Viatris Inc. — News

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com - 2026-07-10 10:41:07

Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?

zacks.com - 2026-07-09 12:40:44

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

zacks.com - 2026-07-09 10:41:32

Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash, growing earnings, and reaffirming guidance.

247wallst.com - 2026-07-07 13:19:51

Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.

fool.com - 2026-07-06 13:09:01

Does Viatris (VTRS) have what it takes to be a top stock pick for momentum investors? Let's find out.

zacks.com - 2026-07-02 13:01:13

PITTSBURGH, July 1, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report second-quarter 2026 financial results on Thursday, August 6, 2026. Company executives will host a conference call and live webcast at 8:30 a.m.

prnewswire.com - 2026-07-01 06:59:00

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-06-29 10:50:24

VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well Tolerated VR-205 Efficacy and Safety Profile in Japanese Patients Was Consistent with the Profile Observed in Global Studies  Japanese New Drug Application Submission Targeted by End of 2026 PITTSBURGH and TOKYO, June 29, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of VR-205 (targeted-release budesonide formulation) (Nefecon®) in Japanese adult patients with primary immunoglobulin A nephropathy (IgAN) at risk of developing end-stage renal disease. The Phase 3 clinical trial was a multicenter, interventional, open-label study designed to evaluate the efficacy and safety of 16 mg of VR-205 in Japanese adult patients with primary IgAN.

prnewswire.com - 2026-06-29 06:59:00

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com - 2026-06-24 10:41:40

Viatris Inc. ends the first half of 2026 on a high note. On May 8, its stock reached a 52-week high of $17.53. One of the key drivers behind Viatris' recent rally is its pipeline, which includes more than 10 late-stage product candidates.

seekingalpha.com - 2026-06-23 12:55:55

Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?

zacks.com - 2026-06-23 12:41:04

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

zacks.com - 2026-06-23 10:40:42

Sandoz, Teva and Viatris target biosimilars, complex generics and specialty drugs as new growth drivers reshape the Medical - Generic Drugs industry.

zacks.com - 2026-06-05 12:50:40

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-06-04 10:41:09

Compare expense ratios, diversification, and risk profiles as these two value-focused ETFs take distinct approaches to portfolio construction.

fool.com - 2026-05-27 11:30:05

A closer look at portfolio makeup, yield, and risk reveals what sets these two iShares healthcare funds apart for investors seeking sector exposure.

fool.com - 2026-05-27 11:17:39

VTRS' fast-acting meloxicam NDA enters FDA review as a non-opioid acute pain therapy, with a decision expected by Dec. 27, 2026.

zacks.com - 2026-05-19 12:41:09

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-05-18 10:50:16

FDA PDUFA Goal Date Set for Dec. 27, 2026 PITTSBURGH, May 18, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of Dec. 27, 2026.

prnewswire.com - 2026-05-18 08:00:00

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-05-13 10:40:19

Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-12 16:00:56

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-05-12 10:46:07

Viatris (VTRS) is upgraded to Strong Buy, underpinned by robust pipeline catalysts and a credible long-term growth framework. Viatris targets a five-year sales CAGR midpoint of 3.5%, exceeding consensus, with $450–550 million annual new product contributions and upside from branded assets. Key assets such as Selatogrel and Cenerimod, alongside upcoming launches (e.g., meloxicam), support reacceleration in growth and margin expansion.

seekingalpha.com - 2026-05-12 04:54:00

Viatris Inc. delivered a clean Q1 2026 double beat driven almost entirely by Greater China, growing 18% operationally. The pipeline is finally shipping after years of underwhelming execution with Effexor and XULANE LO, while other assets will see their readout events in 2027. After Viatris Inc.'s 89% rally, the asymmetric value setup is gone, and while the stock is still cheap, it is not compensating for the associated risk in investing in VTRS stock now.

seekingalpha.com - 2026-05-11 12:55:46

PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12, 2026, at 8 a.m. PT / 11 a.m.

prnewswire.com - 2026-05-07 16:30:00

VTRS beats Q1 estimates as revenues climb 8% on strong Greater China and brands sales, while management reaffirms 2026 guidance.

zacks.com - 2026-05-07 14:41:16

Viatris Inc. (VTRS) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-07 14:21:18

Viatris topped analysts' estimates for first-quarter revenue and profit on Thursday, ​buoyed by strength in its China business and strong demand for ‌branded drugs.

reuters.com - 2026-05-07 12:30:07

While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

zacks.com - 2026-05-07 10:31:33

Viatris (VTRS) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.5 per share a year ago.

zacks.com - 2026-05-07 09:55:51

Delivers Total Revenues of $3.5 Billion, Representing 8% Reported Growth Compared to First Quarter 2025, and U.S. GAAP Net Earnings of $176 Million Total Revenues Were Up 3% Operationally Compared to First Quarter 2025 Adjusted EBITDA was $1.0 Billion Up 10% Operationally Compared to First Quarter 2025, Demonstrating Solid Operating Leverage Progresses Key Launches and Pipeline Milestones Across Multiple Products, Including the Launch of Effexor® for Generalized Anxiety Disorder in Japan Continues to Expect More Than $2.5 Billion of Cash Available for Deployment in 2026 Reaffirms 2026 Financial Guidance [1] PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced its first-quarter 2026 financial results. Executive Commentary "We delivered a strong first quarter, reflecting disciplined execution across our global businesses," said Scott A.

prnewswire.com - 2026-05-07 06:59:00

Beyond analysts' top-and-bottom-line estimates for Viatris (VTRS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.

zacks.com - 2026-05-06 10:15:37

VTRS gears up to report Q1 results as import alerts, regional pressures and growth in key brands shape expectations ahead of May 7 release.

zacks.com - 2026-05-05 14:20:17

PITTSBURGH, May 5, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on May 4, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on June 17, 2026, to shareholders of record as of the close of business on May 22, 2026.

prnewswire.com - 2026-05-05 06:59:00

Theodora "Doretta" Mistras to Depart; Paul Campbell Named Interim CFO PITTSBURGH, May 4, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Theodora "Doretta" Mistras, Chief Financial Officer, will depart the Company for a new professional opportunity. Viatris has named Paul Campbell, currently Chief Accounting Officer and Corporate Controller, as interim Chief Financial Officer, effective May 8, 2026, while the Company conducts its search for a permanent successor.

prnewswire.com - 2026-05-04 16:30:00

PITTSBURGH, May 1, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that six abstracts on its investigational low-dose estrogen combined hormonal contraceptive (CHC) weekly patch will be presented at the 2026 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting (ACSM) in Washington, D.C., May 1-3, 2026.

prnewswire.com - 2026-05-01 06:59:00

Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-30 11:01:20